Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | B2M S14fs |
Therapy | Pembrolizumab |
Indication/Tumor Type | melanoma |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
B2M S14fs | melanoma | predicted - resistant | Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical study, a melanoma patient treated with Keytruda (pembrolizumab) initially demonstrated a partial response, however, post 453 days, developed disease progression likely due to the secondary resistance mutation, B2M S14fs (PMID: 27433843). | 27433843 |
PubMed Id | Reference Title | Details |
---|---|---|
(27433843) | Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. | Full reference... |